Cited 18 times in
A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 이정윤 | - |
dc.date.accessioned | 2019-12-18T01:12:24Z | - |
dc.date.available | 2019-12-18T01:12:24Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173416 | - |
dc.description.abstract | BACKGROUND: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed death-ligand 1 antibody) and tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4 antibody) to chemotherapy in treating this cancer can increase progression-free survival (PFS) with minimal effects on safety. METHODS: During treatment, serial biopsies will be performed on pre-treatment, at interval debulking surgery and progression to identify immune biomarkers and changes in the tumor microenvironment. Patients with histologically confirmed stage IIIC/IV epithelial ovarian cancer are offered durvalumab, tremelimumab plus chemotherapy for neoadjuvant chemotherapy and durvalumab plus chemotherapy for adjuvant chemotherapy. Twenty-four patients will be included from four Korean institutions within 1 year. The primary endpoint is a 12-month PFS rate. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03899610. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D | - |
dc.title.alternative | . | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | Jung-Yun Lee | - |
dc.contributor.googleauthor | Jae Weon Kim | - |
dc.contributor.googleauthor | Myong Cheol Lim | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Hee Seung Kim | - |
dc.contributor.googleauthor | Chel Hun Choi | - |
dc.contributor.googleauthor | Ju Yeon Yi | - |
dc.contributor.googleauthor | Sang-Yoon Park | - |
dc.contributor.googleauthor | Byoung-Gie Kim | - |
dc.identifier.doi | 10.3802/jgo.2019.30.e112 | - |
dc.contributor.localId | A00595 | - |
dc.contributor.localId | A04638 | - |
dc.relation.journalcode | J01428 | - |
dc.identifier.eissn | 2005-0399 | - |
dc.identifier.pmid | 31576697 | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Durvalumab | - |
dc.subject.keyword | Epithelial Ovarian Cancer | - |
dc.subject.keyword | Immunotherapy | - |
dc.subject.keyword | Tremelimumab | - |
dc.contributor.alternativeName | Kim, Sung Hoon | - |
dc.contributor.affiliatedAuthor | 김성훈 | - |
dc.contributor.affiliatedAuthor | 이정윤 | - |
dc.citation.volume | 30 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | e112 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, Vol.30(6) : e112, 2019 | - |
dc.identifier.rimsid | 63667 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.